Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:November 15, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Multiple MyelomaLast Updated:November 15, 2023Recruiting
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:January 24, 2024Not yet recruiting
Condition(s):AL AmyloidosisLast Updated:March 14, 2023Recruiting
Condition(s):Multiple MyelomaLast Updated:December 13, 2023Terminated
Condition(s):Refractory Multiple Myeloma; Relapse Multiple MyelomaLast Updated:August 7, 2023Recruiting
Condition(s):Relapsed Plasmablastic Lymphoma; Refractory Plasmablastic Lymphoma; Anaplastic Lymphoma Kinase Positive Large B-Cell LymphomaLast Updated:July 7, 2023Recruiting
Condition(s):MyelomaLast Updated:December 7, 2023Recruiting
Condition(s):Myeloma MultipleLast Updated:March 15, 2024Recruiting
Condition(s):MyelomaLast Updated:October 12, 2023Recruiting
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:March 12, 2024Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.